Supernus Announces Fourth Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Supernus Pharma (SUPN) Tops Q4 EPS by 2c
February 25, 2020 4:44 PM ESTSupernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.62, $0.02 better than the analyst estimate of $0.60. Revenue for the quarter came in at $100.45 million versus the consensus estimate of $111.53 million.
GUIDANCE:
Supernus Pharma sees FY2020 revenue of $360-390 million, versus the consensus of... More
